Rep. Lisa C. McClain Sells Off Shares of GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Representative Lisa C. McClain sold shares of GSK PLC Sponsored ADR (NYSE:GSK) valued between $1,001 and $15,000 on June 24th, as disclosed in a recent filing.
• GSK reported a quarterly earnings per share (EPS) of $1.23, exceeding the consensus estimate of $1.12, with a revenue of $10.64 billion compared to the estimated $7.92 billion.
• GSK's recent quarterly dividend of $0.4206 per share yields 4.3%, with the dividend payout ratio at 79.17%.

Representative Lisa C. McClain (R-Michigan) recently sold shares of GSK PLC Sponsored ADR NYSE: GSK. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on June 24th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

GSK Price Performance

GSK stock opened at $39.30 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $80.14 billion, a PE ratio of 18.19, a P/E/G ratio of 1.71 and a beta of 0.51. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The business's fifty day moving average price is $38.50 and its 200 day moving average price is $37.97.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is 79.17%.

Analyst Upgrades and Downgrades

GSK has been the topic of several research analyst reports. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, GSK has a consensus rating of "Hold" and an average price target of $37.38.

Institutional Investors Weigh In On GSK

Large investors have recently bought and sold shares of the stock. Twin Peaks Wealth Advisors LLC purchased a new position in shares of GSK in the 2nd quarter valued at about $25,000. HHM Wealth Advisors LLC increased its holdings in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of GSK in the 1st quarter valued at about $31,000. SOA Wealth Advisors LLC. increased its holdings in shares of GSK by 252.1% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock valued at $32,000 after acquiring an additional 605 shares during the last quarter. Finally, Richardson Financial Services Inc. boosted its position in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.